EggenerS, SalomonG, ScardinoPTet al.Focal therapy for prostate cancer: Possibilities and limitations. Eur Urol, 2010; 58:57–64.
2.
de la RosetteJ, AhmedH, BarentszJet al.Focal therapy in prostate cancer—report from a consensus panel. J Endourol, 2010; 24:775–780.
3.
BottSR, HendersonA, McLartyE, LangleySE. A brachytherapy template approach to standardize saturation prostatic biopsy. BJU Int, 2004; 93:629–630.
4.
MadersbacherS, PedevillaM, VingersLet al.Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res, 1995; 55:3346–3351.
5.
El FegounAB, BarretE, PrapotnichDet al.Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 years follow-up. Int Braz J Urol, 2011; 37:213–222.
6.
http://clinicaltrials.gov/ct2/results?term=hifu+prostate+cancer&Search=Search2013Ref Type: Online Source2013 February 22.
7.
TruesdaleMD, CheethamPJ, HrubyGWet al.An evaluation of patient selection criteria on predicting progression-free survival after primary focal unilateral nerve-sparing cryoablation for prostate cancer: recommendations for follow up. Cancer J, 2010; 16:544–549.
8.
BahnDK, LeeF, BadalamentRet al.Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology, 2002; 60,suppl 1:3–11.
9.
OnikG, VaughanD, LotenfoeRet al.“Male lumpectomy”: Focal therapy for prostate cancer using cryoablation. Urology, 2007; 70,suppl 6:16–21.
10.
Assessing the potential for reduced toxicity using focal brachytherapy in early stage, low volume prostate cancer. http://clinicaltrials.gov/show/NCT01354951. 2013 February 8.
11.
CossetJM, WakilG, PierratNet al.Focal brachytherapy for prostate cancer: A pilot study. Radiother Oncol, 2011; 99,suppl 1:S283.
12.
LangleyS, AhmedHU, Al-QaisiehBet al.Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer. BJU Int, 2012; 109,suppl 1:7–16.
13.
MooreCM, PendseD, EmbertonM. Photodynamic therapy for prostate cancer—a review of current status and future promise. Nat Clin Pract Urol, 2009; 6:18–30.
DavalosRV, MirIL, RubinskyB. Tissue ablation with irreversible electroporation. Ann Biomed Eng, 2005; 33:223–231.
17.
BallC, ThomsonKR, KavnoudiasH. Irreversible electroporation: A new challenge in “out of operating theater” anesthesia. Anesth Analg, 2010; 110:1305–1309.
18.
AltuncS. Subnanosecond pulsed-power generated electric fields for cancer treatment. IEEE Nucl Plasma Sci Soc News, 34,20092012.
19.
GarnerAL, ChenG, ChenNet al.Ultrashort electric pulse induced changes in cellular dielectric properties. Biochem Biophys Res Commun, 2007; 362:139–144.
20.
MillerL, LeorJ, RubinskyB. Cancer cells ablation with irreversible electroporation. Technol Cancer Res Treat, 2005; 4:699–705.
21.
RubinskyB, OnikG, MikusP. Irreversible electroporation: A new ablation modality—clinical implications. Technol Cancer Res Treat, 2007; 6:37–48.
FarojaM, AhmedM, AppelbaumLet al.Irreversible electroporation ablation: Is all the damage nonthermal?Radiology, 2013; 266:462–470.
24.
D'AmicoAV, MoulJ, CarrollPRet al.Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol, 2003; 21:2163–2172.
